Nail psoriasis as a severity indicator: results from the PsoReal study
- PMID: 22915964
- PMCID: PMC3417918
- DOI: 10.2147/PROM.S14861
Nail psoriasis as a severity indicator: results from the PsoReal study
Abstract
Background: Although nail psoriasis affects a substantial proportion of psoriasis patients and causes significant psychologic distress, few epidemiologic data characterizing patients with nail involvement are available. The aim of this research was to elucidate differences between patients with nail psoriasis and those without any nail involvement, taking quality indicators of health care from the patient's perspective into account.
Methods: In total, 2449 patient members of the Deutscher Psoriasis Bund, the largest patient organization for psoriasis in Germany, were interviewed in this nationwide, noninterventional, cross-sectional study. Patients with nail psoriasis were compared with patients without any nail involvement with regard to gender, age, disease duration, affected body surface area, health-related quality of life (Dermatology Life Quality Index [DLQI] ED-5D), patient-defined treatment benefit, amount of inpatient treatments, disease duration, and numbers of work days lost.
Results: Data from 2449 patients with psoriasis were analyzed. Overall, 44.8% (1078) of patients were female, mean age was 57.0 ± 11.7 years, and 72.8% had nail involvement and showed higher values for affected body surface area than those without nail involvement (8.3% versus 5.6%, respectively; P < 0.004). Health-related quality of life was significantly lower in patients with nail psoriasis (DLQI 7.2 versus 5.3; ED-5D 60.1 versus 67.3), who had more days off work (9.8 versus 3.3).
Conclusion: Nail involvement is an important symptom of psoriasis and is associated with greater disease severity and quality of life impairment. Accordingly, management of psoriasis should include a special focus on nail involvement.
Keywords: health services research; nails; psoriasis; quality indicators; quality of life.
Similar articles
-
The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.Skin Appendage Disord. 2021 Feb;7(2):83-89. doi: 10.1159/000512688. Epub 2021 Jan 22. Skin Appendage Disord. 2021. PMID: 33796553 Free PMC article.
-
Quality of psoriasis care from the patients' perspective--results of the national health care study PsoReal.Eur J Dermatol. 2012 Jul-Aug;22(4):518-24. doi: 10.1684/ejd.2012.1740. Eur J Dermatol. 2012. PMID: 22575816
-
The relationship between quality of life and the severity of psoriasis in Turkey.Eur J Dermatol. 2015 Apr;25(2):169-76. doi: 10.1684/ejd.2014.2511. Eur J Dermatol. 2015. PMID: 25655046
-
Adalimumab for the treatment of moderate to severe psoriasis: subanalysis of effects on scalp and nails in the BELIEVE study.J Eur Acad Dermatol Venereol. 2015 Feb;29(2):353-360. doi: 10.1111/jdv.12553. Epub 2014 May 21. J Eur Acad Dermatol Venereol. 2015. PMID: 24846518 Clinical Trial.
-
Management of nail psoriasis.Clin Exp Dermatol. 2021 Jan;46(1):3-8. doi: 10.1111/ced.14314. Epub 2020 Aug 2. Clin Exp Dermatol. 2021. PMID: 32741010 Review.
Cited by
-
Nail Psoriasis and Quality-of-Life Measurement in Clinical Trials: Call for the Use of Nail-Specific Instruments.Am J Clin Dermatol. 2021 Nov;22(6):747-755. doi: 10.1007/s40257-021-00622-7. Epub 2021 Aug 12. Am J Clin Dermatol. 2021. PMID: 34383273 Free PMC article.
-
Comparison of the Objective Severity and the Esthetic Perception of Nail Symptoms in Psoriasis.Skin Appendage Disord. 2022 Jul;8(4):295-301. doi: 10.1159/000521930. Epub 2022 Feb 14. Skin Appendage Disord. 2022. PMID: 35979525 Free PMC article.
-
The Impact of Nail Psoriasis and Treatment on Quality of Life: A Systematic Review.Skin Appendage Disord. 2021 Feb;7(2):83-89. doi: 10.1159/000512688. Epub 2021 Jan 22. Skin Appendage Disord. 2021. PMID: 33796553 Free PMC article.
-
Secukinumab Exhibits Sustained and Stable Response in Patients with Moderate-to-Severe Psoriasis: Results from the SUPREME Study.Acta Derm Venereol. 2021 Oct 21;101(10):adv00576. doi: 10.2340/00015555-3816. Acta Derm Venereol. 2021. PMID: 33903916 Free PMC article. Clinical Trial.
-
Toenail Psoriasis during Ustekinumab Therapy: Results and Limitations.Ann Dermatol. 2021 Apr;33(2):131-137. doi: 10.5021/ad.2021.33.2.131. Epub 2021 Mar 8. Ann Dermatol. 2021. PMID: 33935454 Free PMC article.
References
-
- Lawry M. Biological therapy and nail psoriasis. Dermatol Ther. 2007;20:60–67. - PubMed
-
- Farber EM, Nall L. Nail psoriasis. Cutis. 1992;50:174–178. - PubMed
-
- Van Laborde S, Scher RK. Developments in the treatment of nail psoriasis, melanonychia striata, and onychomycosis. A review of the literature. Dermatol Clin. 2000;18:37–46. - PubMed
-
- Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008;216:366–372. - PubMed
-
- Leung YY, Tam LS, Kun EW, Li EK. Psoriatic arthritis as a distinct disease entity. J Postgrad Med. 2007;53:63–71. - PubMed
LinkOut - more resources
Full Text Sources